Eli Lilly has unveiled plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis, IN. The plans are driven by increasing demand for Lilly’s current medicines, and they provide additional manufacturing capacity for future medicines coming from Lilly’s pipeline. These new investments will create approximately 100 new jobs at the company.
 
Company leaders were joined by state and local government officials at Lilly’s headquarters in Indianapolis to unveil the details of the investments, which include enhancements to existing manufacturing facilities that make insulin, additional capacity for its growing portfolio of diabetes medicines and initial capital investments for future medicines.
 
“These investments demonstrate Lilly’s commitment to our manufacturing footprint in Indiana and the United States, and have been made possible by the tax reform measures passed by Congress in 2017,” said David A. Ricks, Lilly’s chairman and chief executive officer. “With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production here at home. This is crucial for us to continue to advance our state’s economy and drive future investment—adding high-tech jobs and facilities that keep Indiana competitive in the global marketplace.”
 
Myles O’Neill, senior vice president and president of manufacturing operations, Lilly, said, “These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations. All of these projects support Lilly’s investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics.”
 
O’Neill noted that in addition to increasing the capacity and capabilities needed to provide a safe and reliable supply of medicine for people, the investments also allow Lilly to add highly skilled U.S. manufacturing jobs. “To make medicine, we need highly skilled technicians, scientists and engineers, who are economic catalysts for local communities,” he said.
 
Lilly has invested over $5 billion in the U.S. since 2012, with the majority of this investment in its Indiana facilities and nearly $2 billion in manufacturing of diabetes medicines.